These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29076559)

  • 1. Genetic influences on cognition in progressive supranuclear palsy.
    Gerstenecker A; Roberson ED; Schellenberg GD; Standaert DG; Shprecher DR; Kluger BM; Litvan I
    Mov Disord; 2017 Dec; 32(12):1764-1771. PubMed ID: 29076559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive impairment in progressive supranuclear palsy is associated with tau burden.
    Koga S; Parks A; Kasanuki K; Sanchez-Contreras M; Baker MC; Josephs KA; Ahlskog JE; Uitti RJ; Graff-Radford N; van Gerpen JA; Wszolek ZK; Rademakers R; Dickson DW
    Mov Disord; 2017 Dec; 32(12):1772-1779. PubMed ID: 29082658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of common variability and expression quantitative trait loci for genome-wide associations for progressive supranuclear palsy.
    Ferrari R; Ryten M; Simone R; Trabzuni D; Nicolaou N; Hondhamuni G; Ramasamy A; Vandrovcova J; ; Weale ME; Lees AJ; Momeni P; Hardy J; de Silva R
    Neurobiol Aging; 2014 Jun; 35(6):1514.e1-12. PubMed ID: 24503276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy.
    Kouri N; Ross OA; Dombroski B; Younkin CS; Serie DJ; Soto-Ortolaza A; Baker M; Finch NCA; Yoon H; Kim J; Fujioka S; McLean CA; Ghetti B; Spina S; Cantwell LB; Farlow MR; Grafman J; Huey ED; Ryung Han M; Beecher S; Geller ET; Kretzschmar HA; Roeber S; Gearing M; Juncos JL; Vonsattel JPG; Van Deerlin VM; Grossman M; Hurtig HI; Gross RG; Arnold SE; Trojanowski JQ; Lee VM; Wenning GK; White CL; Höglinger GU; Müller U; Devlin B; Golbe LI; Crook J; Parisi JE; Boeve BF; Josephs KA; Wszolek ZK; Uitti RJ; Graff-Radford NR; Litvan I; Younkin SG; Wang LS; Ertekin-Taner N; Rademakers R; Hakonarsen H; Schellenberg GD; Dickson DW
    Nat Commun; 2015 Jun; 6():7247. PubMed ID: 26077951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
    Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
    Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The PSP-associated MAPT H1 subhaplotype in Guadeloupean atypical parkinsonism.
    Camuzat A; Romana M; Dürr A; Feingold J; Brice A; Ruberg M; Lannuzel A
    Mov Disord; 2008 Dec; 23(16):2384-91. PubMed ID: 18785640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy.
    Chen Z; Chen JA; Shatunov A; Jones AR; Kravitz SN; Huang AY; Lawrence L; Lowe JK; Lewis CM; Payan CAM; Lieb W; Franke A; Deloukas P; Amouyel P; Tzourio C; Dartigues JF; ; Ludolph A; Bensimon G; Leigh PN; Bronstein JM; Coppola G; Geschwind DH; Al-Chalabi A
    Mov Disord; 2019 Jul; 34(7):1049-1059. PubMed ID: 31059154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
    Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
    JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
    Brown RG; Lacomblez L; Landwehrmeyer BG; Bak T; Uttner I; Dubois B; Agid Y; Ludolph A; Bensimon G; Payan C; Leigh NP;
    Brain; 2010 Aug; 133(Pt 8):2382-93. PubMed ID: 20576697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases.
    Morris HR; Janssen JC; Bandmann O; Daniel SE; Rossor MN; Lees AJ; Wood NW
    J Neurol Neurosurg Psychiatry; 1999 May; 66(5):665-7. PubMed ID: 10209184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different MAPT haplotypes are associated with Parkinson's disease and progressive supranuclear palsy.
    Ezquerra M; Pastor P; Gaig C; Vidal-Taboada JM; Cruchaga C; Muñoz E; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    Neurobiol Aging; 2011 Mar; 32(3):547.e11-6. PubMed ID: 19879020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy.
    Morris HR; Schrag A; Nath U; Burn D; Quinn NP; Daniel S; Wood NW; Lees AJ
    Neurosci Lett; 2001 Oct; 312(2):118-20. PubMed ID: 11595348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide association study identifies
    Chen J; Yu JT; Wojta K; Wang HF; Zetterberg H; Blennow K; Yokoyama JS; Weiner MW; Kramer JH; Rosen H; Miller BL; Coppola G; Boxer AL;
    Neurology; 2017 Feb; 88(7):669-676. PubMed ID: 28100725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype.
    Poorkaj P; Muma NA; Zhukareva V; Cochran EJ; Shannon KM; Hurtig H; Koller WC; Bird TD; Trojanowski JQ; Lee VM; Schellenberg GD
    Ann Neurol; 2002 Oct; 52(4):511-6. PubMed ID: 12325083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of Progressive Supranuclear Palsy: A Review.
    Wen Y; Zhou Y; Jiao B; Shen L
    J Parkinsons Dis; 2021; 11(1):93-105. PubMed ID: 33104043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and cognitive correlations of regional gray matter atrophy in progressive supranuclear palsy.
    Giordano A; Tessitore A; Corbo D; Cirillo G; de Micco R; Russo A; Liguori S; Cirillo M; Esposito F; Tedeschi G
    Parkinsonism Relat Disord; 2013 Jun; 19(6):590-4. PubMed ID: 23477861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.
    Rittman T; Rubinov M; Vértes PE; Patel AX; Ginestet CE; Ghosh BCP; Barker RA; Spillantini MG; Bullmore ET; Rowe JB
    Neurobiol Aging; 2016 Dec; 48():153-160. PubMed ID: 27697694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic bases of Progressive Supranuclear Palsy: the MAPT tau disease.
    Borroni B; Agosti C; Magnani E; Di Luca M; Padovani A
    Curr Med Chem; 2011; 18(17):2655-60. PubMed ID: 21568901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.
    Gerstenecker A; Mast B; Duff K; Ferman TJ; Litvan I;
    Arch Clin Neuropsychol; 2013 Mar; 28(2):104-13. PubMed ID: 23127882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.